JUUL Litigation Moving Forward in MDL, As Growing Number of Lawsuits Filed Over Vaping Problems

JUUL Labs now faces nearly 300 lawsuits brought by teens, parents, and a number of school districts nationwide, each raising similar allegations that the e-cigarette’s design and marketing strategy resulted in widespread JUUL nicotine addictions among teens, which appears to be part of an intentional strategy to hook life-long users of their products.

Given similar questions of fact and law presented in claims filed throughout the federal court system, the JUUL lawsuits are now consolidated before U.S. District Judge William H. Orrick III in the U.S. District Court for the Northern District of California, which is where JUUL Labs, Inc.’s San Francisco headquarters are located.

As more parents and young adults step forward to pursue claims after after becoming addicted to JUUL, it is widely expected that the size of the litigation will continue to grow over the coming months and years.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

According to minutes (PDF) from a recent status conference held to discuss the early status of the litigation, Judge Orrick encouraged the parties to continue working together to resolve discovery disputes and suggested that they consider an effective approach and timing for discussions about potential JUUL settlements that may resolve the litigation.

In addition, Judge Orrick requested parties submit a list of all pending motions and a proposed timeframe to resolve them by the next conference, which will be held on February 14.

JUUL Teen Addiction Problems

Recent FDA data indicates teen e-cigarette use has reached epidemic levels in the United States, and JUUL Labs has been accused of fueling the growing teen nicotine addiction problems in the United States, through the design and marketing of their vape pen.

JUUL was intentionally designed to look like a USB thumb drive, which has made the product popular among teems who are able to hide their vaping habit from parents, teachers and other adults.

The manufacturer also marketed and sold JUUL in various candy-like flavors, which has resulted in a large number of teens and prior non-smokers starting to vape, and developing addictions to the high levels of nicotine contained in the pods.

As part of the consolidation into a MDL, all pretrial proceedings will be handled by Judge Orrick, but the cases will remain individual lawsuits. If settlements or another resolution is not reached during the pretrial proceedings, each case may eventually be transferred back to their originating districts for trial in the future.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted today)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 2 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.